BioWorld Insight analyzes critical components of the biopharma industry, from insights into which products are ahead or behind in a particular product space, the potential impact of new and pending regulatory rules and ideas for generating capital funding that is the lifeblood of the industry.
Every Monday – you'll have the behind-the-scenes analysis plus:
Our BioWorld Stock Report for U.S. publicly traded companies, listings for the London and Toronto stock exchanges, plus the 10 biggest gainers and losers for the week.
Find out who is ahead in niche markets, new and pending regulation, and ideas for generating the capital that is the lifeblood of the industry.
Insight examines business challenges – and potential solutions – that constantly face both industry giants and brand new start-ups.
Inside each issue – our exclusive charts and graphs to key biopharma metrics – available nowhere else:
Clinical trial updates separated by indication (cancer, diabetes, etc.), plus FDA actions
Details of collaborations and deal modifications
Public financing and private
Public offering performance by underwriters
BioWorld Insight – the analytical companion to BioWorld Today for executives who demand the winning edge!